Jeffrey Ecsedy - 02 Feb 2022 Form 4 Insider Report for Ikena Oncology, Inc. (IKNA)

Role
Chief Development Officer
Signature
/s/ Douglas R. Carlson, as Attorney-in-Fact for Jeffrey Ecsedy
Issuer symbol
IKNA
Transactions as of
02 Feb 2022
Net transactions value
$0
Form type
4
Filing time
04 Feb 2022, 17:10:55 UTC
Next filing
05 Jan 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction IKNA Stock Option (Right to Buy) Award $0 +59,360 $0.000000 59,360 02 Feb 2022 Common Stock 59,360 $11.45 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 25% of the shares subject to this option shall vest and become exercisable on January 1, 2023, with the remainder vesting in 36 substantially equal monthly installments thereafter.